KRAS and neoplasm: Skoulidis et al., focusing on KRAS mutant LUACs, revealed different co-mutational subsets of KRAS mutants with distinct biologic and vulnerabilities and immune profiles [36] and showed that KL tumors exhibited lower densities of CD3+ and CD8+ lymphocytes, but not FOXP3+ cells, and lacked PD-L1 expression in the tumor cells despite intermediate–high TMB [37].